Verona Pharma plc financial data

Symbol
VRNA on Nasdaq
Industry
Pharmaceutical Preparations
Location
3 More London Riverside, London, United Kingdom
State of incorporation
United Kingdom
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 4, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.35K % -20.9%
Debt-to-equity 82.9 % +540%
Return On Equity -79.5 % -310%
Return On Assets -43.5 % -153%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 655M shares +2.37%
Common Stock, Shares, Outstanding 655M shares +2.37%
Entity Public Float 1.5B USD +607%
Common Stock, Value, Issued 42.8M USD +2.44%
Weighted Average Number of Shares Outstanding, Basic 652M shares +2.15%
Weighted Average Number of Shares Outstanding, Diluted 652M shares +2.15%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 5.62M USD
Research and Development Expense 44.3M USD -47%
General and Administrative Expense 120M USD +174%
Operating Income (Loss) -155M USD -145%
Nonoperating Income (Expense) 3.62M USD -72.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -152M USD -203%
Income Tax Expense (Benefit) 1.97M USD +254%
Net Income (Loss) Attributable to Parent -154M USD -203%
Earnings Per Share, Basic -0.25 USD/shares -257%
Earnings Per Share, Diluted -0.25 USD/shares -257%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 336M USD +30.6%
Accounts Receivable, after Allowance for Credit Loss, Current 6.9M USD
Inventory, Net 4.32M USD
Other Assets, Current 3.44M USD -45.5%
Assets, Current 364M USD +31.7%
Property, Plant and Equipment, Net 40K USD +300%
Operating Lease, Right-of-Use Asset 1.98M USD +410%
Goodwill 545K USD 0%
Assets 382M USD +30.5%
Accounts Payable, Current 6.83M USD +730%
Employee-related Liabilities, Current 7.27M USD +98.2%
Accrued Liabilities, Current 18.1M USD +145%
Contract with Customer, Liability, Current 169K USD
Liabilities, Current 28M USD +210%
Operating Lease, Liability, Noncurrent 1.35M USD +6645%
Liabilities 251M USD +769%
Accumulated Other Comprehensive Income (Loss), Net of Tax -4.6M USD 0%
Retained Earnings (Accumulated Deficit) -528M USD -41.3%
Stockholders' Equity Attributable to Parent 130M USD -50.5%
Liabilities and Equity 382M USD +30.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -13.6M USD -135%
Net Cash Provided by (Used in) Financing Activities -3.12M USD -105%
Net Cash Provided by (Used in) Investing Activities -16K USD
Common Stock, Shares, Issued 668M shares +2.46%
Common Stock, Par or Stated Value Per Share 0.05 GBP/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -16.9M USD -127%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 336M USD +30.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 933K USD +282%
Deferred Tax Assets, Valuation Allowance 55.5M USD +14.5%
Deferred Tax Assets, Gross 109M USD +31.7%
Operating Lease, Liability 2.96M USD +236%
Payments to Acquire Property, Plant, and Equipment 16K USD
Lessee, Operating Lease, Liability, to be Paid 3.59M USD +296%
Operating Lease, Liability, Current 952K USD +153%
Lessee, Operating Lease, Liability, to be Paid, Year Two 842K USD +292%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.18M USD +74.1%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 634K USD +2248%
Lessee, Operating Lease, Liability, to be Paid, Year Three 788K USD +4535%
Deferred Tax Assets, Operating Loss Carryforwards 54M USD +38.9%
Lessee, Operating Lease, Liability, to be Paid, Year Four 784K USD
Additional Paid in Capital 622M USD +3.4%
Depreciation, Depletion and Amortization 263K USD +67.5%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 32.1M USD +69.3%
Interest Expense 13.8M USD +732%